BioMimetic Therapeutics, Inc. (BMTI) - Product Pipeline Analysis

Document Sample
BioMimetic Therapeutics, Inc. (BMTI)  - Product Pipeline Analysis Powered By Docstoc
					                    BioMimetic Therapeutics, Inc. (BMTI) - Product Pipeline Analysis

     Reference Code: GDMEPH2437PD                                                                                             Publication Date: NOV 2010



     Company Snapshot                                                        Company Overview
     Key Information
                                                                             BioMimetic Therapeutics, Inc. (BioMimetic) is a biotechnology company
      BioMimetic Therapeutics, Inc., Key Facts                               utilizing purified recombinant human platelet-derived growth factor
                                                                             (rhPDGF-BB) in combination with tissue specific matrices as its primary
      Web Address                           www.biomimetics.com
                                                                             technology platform for promotion of tissue healing and regeneration. It is
      Turnover (in USD Million) 1.60                                         engaged in the development and commercialization of drug-device
                                                                             combination products that enhance the healing of orthopedic, periodontal,
      Number of Employees                   89                               craniofacial and sports injuries. Further, the company’s range of products
      Industry                              Pharmaceuticals and Healthcare   and product candidates combine recombinant protein therapeutics with
      Source:Primary / Secondary Research                                    tissue specific scaffolds that stimulate tissue healing and regeneration.
      GlobalData                                                             The company has two wholly owned subsidiaries.



     BioMimetic Therapeutics, Inc. Pipeline Products

     BioMimetic Therapeutics, Inc. Key Pipeline Products by                  BioMimetic Therapeutics, Inc. Key Pipeline Products by Therapy
     Equipment Type                                                          Area
     Equipment Type                           No of Products                 Therapy Area                                     No of Products
     Orthobiologics                                  7                       Tendonitis                                              3
     Spinal Surgery                                  1                       Ankle fractures, Foot fracture                          1
                                                                             Cartilage injury                                              1
                                                                             Degenerative disc disease                                     1
                                                                             Foot and ankle joint fractures                                1
                                                                             Rotator cuff injuries                                         1
     Source: Primary / Secondary Research                                    Source: Primary / Secondary Research
     GlobalData                                                              GlobalData


     BioMimetic Therapeutics, Inc. Key Pipeline Products by Equipment Type




      Source: Primary / Secondary Research
      GlobalData




     BioMimetic Therapeutics, Inc. Key Pipeline Products by                  BioMimetic Therapeutics, Inc. Key Pipeline Products by Trial Phase
     Development Stage
     Developmental Stage                  No of Products                     Trial Phase                                    No of Products
     Clinicals                                   1                           Phase IV                                               -
     Pre-Clinicals                               6                           Phase III                                              -
     Early development                                                       Phase II                                               2
                                                               -
     Source: Primary / Secondary Research                                    Phase I                                                2
     GlobalData
     Note : (-) indicates 'Not Available'
                                                                             Source: Primary / Secondary Research
                                                                             GlobalData
                                                                             Note : (-) indicates 'Not Available'




BioMimetic Therapeutics, Inc. (BMTI) - Product Pipeline Analysis                                                                Reference Code: GDMEPH2437PD

Source : www.globalcompanyintelligence.com                                                                                                                 Page 1
     Table of Contents
     Table of Contents................................................................................................................................................................................................................................................................... 2
     List of Tables .......................................................................................................................................................................................................................................................................... 3
     List of Figures......................................................................................................................................................................................................................................................................... 4
     BioMimetic Therapeutics, Inc. - Business Description ........................................................................................................................................................................................................... 5
     Key Facts ............................................................................................................................................................................................................................................................................... 6
     BioMimetic Therapeutics, Inc. - Major Products and Services............................................................................................................................................................................................... 7
           BioMimetic Therapeutics, Inc. Pipeline Products by Equipment Type ............................................................................................................................................................................ 8
           BioMimetic Therapeutics, Inc. Pipeline Products by Development Stage ..................................................................................................................................................................... 10
           BioMimetic Therapeutics, Inc. Pipeline Products by Therapy Area ............................................................................................................................................................................... 12
           BioMimetic Therapeutics, Inc. Pipeline Products by Trial Phase .................................................................................................................................................................................. 14
           BioMimetic Therapeutics, Inc. Pipeline Products by Milestone Summary..................................................................................................................................................................... 16
           Augment AT................................................................................................................................................................................................................................................................... 18
                 Product Status......................................................................................................................................................................................................................................................... 18
                 Product Description ................................................................................................................................................................................................................................................. 18
           Augment Bone Graft ...................................................................................................................................................................................................................................................... 18
                 Product Status......................................................................................................................................................................................................................................................... 18
                 Product Description ................................................................................................................................................................................................................................................. 18
                 Product Milestone ................................................................................................................................................................................................................................................... 19
                 Augment Bone Graft Clinical Trial........................................................................................................................................................................................................................... 20
                 Product Patent Details ............................................................................................................................................................................................................................................ 22
           Augment C..................................................................................................................................................................................................................................................................... 22
                 Product Status......................................................................................................................................................................................................................................................... 22
                 Product Description ................................................................................................................................................................................................................................................. 22
           Augment CT................................................................................................................................................................................................................................................................... 23
                 Product Status......................................................................................................................................................................................................................................................... 23
                 Product Description ................................................................................................................................................................................................................................................. 23
           Augment Injectable Bone Graft...................................................................................................................................................................................................................................... 23
                 Product Status......................................................................................................................................................................................................................................................... 23
                 Product Description ................................................................................................................................................................................................................................................. 23
                 Product Milestone ................................................................................................................................................................................................................................................... 24
                 Augment Injectable Bone Graft Clinical Trial .......................................................................................................................................................................................................... 24
                 Product Pricing ........................................................................................................................................................................................................................................................ 25
                 Product Patent Details ............................................................................................................................................................................................................................................ 26
           Augment LT ................................................................................................................................................................................................................................................................... 26
                 Product Status......................................................................................................................................................................................................................................................... 26
                 Product Description ................................................................................................................................................................................................................................................. 26
           Augment RC .................................................................................................................................................................................................................................................................. 27
                 Product Status......................................................................................................................................................................................................................................................... 27
                 Product Description ................................................................................................................................................................................................................................................. 27
           Augment-Spine .............................................................................................................................................................................................................................................................. 27
                 Product Status......................................................................................................................................................................................................................................................... 27
                 Product Description ................................................................................................................................................................................................................................................. 27
     BioMimetic Therapeutics, Inc. - Key Competitors ................................................................................................................................................................................................................ 28
     BioMimetic Therapeutics, Inc. - Key Employees.................................................................................................................................................................................................................. 29
     BioMimetic Therapeutics, Inc
				
DOCUMENT INFO
Description: BioMimetic Therapeutics, Inc. (BMTI) - Product Pipeline Analysis Summary This report is a source for data, analysis and actionable intelligence on the BioMimetic Therapeutics, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date. Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. Scope - Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments. - Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase. - Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date. - Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application. - Data on relevant clinical trials and product patent details, wherever applicable. - Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender
BUY THIS DOCUMENT NOW PRICE: $750 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.